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A B S T R A C T
Breast cancer is the most prevalent type of malignancy in women with ∼1.7 million new cases diagnosed
annually, of which the majority express ERα (ESR1), a ligand-dependent transcription factor. Genome-wide
chromatin binding maps suggest that ERα may control the expression of thousands of genes, posing a great
challenge in identifying functional targets. Recently, we developed a CRISPR-Cas9 functional genetic screening
approach to identify enhancers required for ERα-positive breast cancer cell proliferation. We validated several
candidates, including CUTE, a putative ERα-responsive enhancer located in the ﬁrst intron of CUEDC1 (CUE-
domain containing protein). Here, we show that CUTE controls CUEDC1 expression, and that this interaction is
essential for ERα-mediated cell proliferation. Moreover, ectopic expression of CUEDC1, but not a CUE-domain
mutant, rescues the defects in CUTE activity. Finally, CUEDC1 expression correlates positively with ERα in
breast cancer. Thus, CUEDC1 is a functional target gene of ERα and is required for breast cancer cell pro-
liferation.
1. Introduction
Breast cancer is the most prevalent type of malignancy in women,
and each year ∼1.7 million new cases are diagnosed [1]. Approxi-
mately 70% of breast tumors express ERα (ESR1), which is a tran-
scription factor (TF) that plays a critical role in cell proliferation [2].
ERα is activated by estradiol (E2), which is its natural ligand, or
through phosphorylation events mediated by kinases such as MAPK/
PI3K [2]. ERα is a ligand-dependent TF that is recruited directly or
indirectly to the chromatin, to activate the expression of target genes
[3]. Currently, ERα is considered as a major drug target in breast cancer
for hormonal therapy, either by inhibiting its association with E2 using
tamoxifen [4] or by preventing estrogen synthesis through aromatase
inhibitors [5]. Despite the extensive use of these drugs, a substantial
number of tumors relapse after initial treatments and patients develop
resistance to therapy [6].
ERα regulates the expression of several genes that play a central role
in the development of breast cancer, including CCND1, E2F1 and Myc
[7]. Chromatin immunoprecipitation and sequencing (ChIP-seq) ex-
periments revealed that the vast majority of ERα binding events map to
regions that have features of enhancers and are distantly located from
protein-coding genes [8,9]. Enhancers are non-coding DNA elements
that control gene expression in space and time, which is critical for
specifying diﬀerent cell-lineages during the development of organisms
[10]. Subsequent studies identiﬁed ∼1200 enhancers that express en-
hancer-associated RNAs (eRNAs) upon activation of ERα in breast
cancer cells [4,11]. eRNA expression is a hallmark of active enhancer
elements [12] and several studies suggest that they are required for the
activation of their target genes [4,11,13]. The studies mentioned above
contributed to elucidate the mode of action of ERα and provided a
comprehensive map of its binding sites throughout the genome
[4,8,11]. However, they are inherently descriptive and do not fully
explain the function and mechanisms of ERα-regulated enhancers.
Moreover, it is not clear which are the primary target genes of ERα and
how they contribute to the proliferation of breast cancer cells.
Traditionally, it is challenging to study the function of enhancers
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due to a lack of genetic tools to manipulate these DNA elements. The
development of CRISPR-Cas9 systems opened exciting possibilities for
targeted genome editing. Of note, Cas9 can be directed to virtually any
genomic sequence by a single guide RNA (sgRNA), provided that there
is a protospacer adjacent motif (PAM) downstream of the target se-
quence [14]. Cas9 is a nuclease that eﬃciently induces double-strand
breaks (DSBs), which give rise to small insertions and deletions (indels)
when repaired by non-homologous end joining (NHEJ). The CRISPR-
Cas9 system is capable of cleaving multiple target sequences in parallel
[15,16], making it particularly suitable to perform genome-wide ge-
netic screens [17,18]. Recently, we and others pioneered the applica-
tion of CRISPR-Cas9 to map functional enhancer elements in human
cells [19–22]. In our work, we performed genetic screens to identify
enhancers that are required for the growth of ERα-dependent breast
cancer cells [20]. We validated three candidate hits from the screen
(enh588, enh1830 and enh1986). Enh588 controls the expression of
CCND1 in ERα-positive breast cancer cells, whereas the function of
enh1986 is not clear to date. Enh1830 is a putative enhancer located in
the ﬁrst intron of CUEDC1 that we named here CUTE (CUEDC1 Tran-
scriptional Enhancer). CUEDC1 is a ubiquitously expressed protein that
contains a CUE domain, and so far is not associated with breast cancer.
Very little is known about the function of CUEDC1 in humans, though
CUE-containing proteins were shown to bind ubiquitin chains to facil-
itate K48 and K63-linked polyubiquitin and protein turnover in yeast
[23]. In particular, a recent large-scale mass spectrometry study con-
ﬁrmed the interaction between K63-linked diubiquitin and human
CUEDC1 [24]. Furthermore, publicly available protein-protein inter-
action data indicated an experimental interaction of human CUEDC1
with TOM1 (target of Myb protein 1), a cellular traﬃcking protein [25].
Here, we show that CUTE is a bona-ﬁde enhancer that activates
CUEDC1 expression in response to ERα signaling. The inactivation of
CUTE signiﬁcantly decreases the expression of CUEDC1 and hampers
cell proliferation. Ectopic expression of CUEDC1 wild-type, but not a
CUE-domain mutant, rescues this phenotype, indicating a key func-
tional role of CUEDC1 within the ERα signaling network. Finally, we
found that expression of CUEDC1 is signiﬁcantly increased in ERα-po-
sitive tumors. All this evidence corroborates that CUEDC1 is a primary
target gene of the estrogen pathway that is required for the proliferation
of breast cancer cells in vivo.
2. Materials and methods
2.1. Cell lines and chemical reagents
MCF-7, MDA-MB-231 and HEK293T cells were cultured in DMEM
(Gibco), supplemented with 10% FCS (Hyclone), and 1% penicillin/
streptomycin (Gibco). For the estrogen-stimulation experiments, MCF-
7 cells were washed 3 times with PBS and cultured in phenol red–free
DMEMmedium (Gibco) supplemented with 5% charcoal stripped serum
(Gibco) for 72 h prior to E2 treatment (10−8 M). E2 (17β-estradiol) was
purchased from Sigma. All cell lines were obtained from the American
Type Culture Collection, and they were tested for mycoplasma.
2.2. Cloning of sgRNAs
Custom sgRNAs were designed using CRISPR Design tool (http://
crispr.mit.edu/) and cloned into lentiCRISPRv2 (gift from Feng Zhang
(Addgene plasmid #52961)) according to the protocol described by the
Zhang lab [17]. The oligos were purchased from IDT and their se-
quences are listed on Table 1.
2.3. Transduction of human cell lines
To produce lentivirus, 4× 106 HEK293T cells were seeded in
100mm dishes one day prior to transfection. For each dish, we mixed
10 μg of the target lentiviral construct, 3.5 μg of pVSV-G, 5 μg of pMDL
RRE and 2.5 μg of pRSV-REV in a total volume of 450 μl, added 50 μl of
CaCl2 and incubated 5min at RT. Plasmid DNA was precipitated by
adding 500 μl 2× HBS to the solution while vortexing at full speed.
Lentivirus-containing supernatants were collected 48 h post-transfec-
tion, ﬁltered through a 0.45 μm membrane (Milipore Steriﬂip HV/
PVDF) and stored at−80 °C. All cell types and lentivirus batches tested
were titrated in order to achieve a multiplicity of infection (MOI) of
∼0.3. Cell lines were infected with lentivirus supernatants supple-
mented with 8 μg/ml polybrene (Sigma). At 24 h post-infection,
medium was replaced and cells were selected with 2 μg/ml puromycin
(Gibco) until there were no cells surviving on the negative control plate
(non-transduced cells).
2.4. DNA-seq
Cell pellets were collected and gDNA was isolated with DNeasy
Blood and Tissue kit (Qiagen). For each sample, we performed two
separate reactions (max. 500 ng of gDNA per reaction) using Phusion
DNA polymerase (Thermo Scientiﬁc) and combined the resulting am-
plicons. Ampliﬁcation was carried out with 18 cycles for both ﬁrst and
second PCR. In the ﬁrst PCR, we used the following primer sequences:
PCR1_F1
ACACTCTTTCCCTACACGACGCTCTTCCGATCTXXXXXXGGCTTTA-
TATATCTTGTGGAAAGGACG (XXXXXX represents a 6 bp barcode)
PCR1_R1
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACTGACGGGCAC
CGGAGCCAATTCC
A second PCR was performed to attach Illumina adaptors and index
samples. The second PCR was done in 50 μl reaction volume, including
5 μl of the product from the ﬁrst PCR, and using the following primers:
PCR2_P5
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG
CTCTTCCGATCT
PCR2_P7
CAAGCAGAAGACGGCATACGAGATXXXXXXGTGACTGGAGTTCAG-
ACGTGTGCTCTTCCGATCT (XXXXXX represents a 6 bp index)
After the second PCR, the amplicons were puriﬁed using Agencourt
AMPure XP beads (Beckman Coulter), quantiﬁed in a Bioanalyzer 2100
(Agilent), and sequenced using a HiSeq 2500 (Illumina).
2.5. RNA isolation, reverse transcription and qPCR
RNA was harvested using TriSure (Bioline) reagent for cell lysis and
Rneasy mini kit (Qiagen) to isolate total RNA according to the manu-
facturer's protocols. cDNA was produced from RNA using Superscript III
(Invitrogen). qPCR experiments were performed in a Lightcycler 480
(Roche) using SYBR green I Master mix (Roche) according to the
manufacturer's protocol. The primers used for this experiment are listed
on Table 2.
Table 1
Sequences of sgRNAs.
Name Oligo 1 (forward) Oligo 2 (reverse)
sg1830 caccgtttacagcattggtaaggtc aaacgaccttaccaatgctgtaaac
sgCUEDC1 exon#1 caccgaccacatgcacgtgttcgac aaacgtcgaacacgtgcatgtggtc
sgCUEDC1 exon#2 caccgtaggctggcggggagtacac aaacgtgtactccccgccagcctac
sgCUEDC1 intron#1 caccgattcccattgaaacccccta aaactagggggtttcaatgggaatc
sgCUEDC1 intron#2 caccgtaaggcttgaggtcaacgat aaacatcgttgacctcaagccttac
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2.6. Western blot
Whole-cell extracts were prepared using RIPA buﬀer (NaCl 150mM;
NP-40 1%; Sodium deoxycholate 0.5%; SDS 0.1%; Tris pH 7.4 25mM),
separated on 10% SDS-PAGE gels and transferred to Immobilon-P
membranes (Millipore). Membranes were immunoblotted with the
following antibodies: V5 (ab27671, Abcam); HSP90 (H-114, Santa Cruz
Biotechnology). Protein bands were visualized using corresponding
secondary antibodies (Dako) and ECL reagent (GE Healthcare).
2.7. Cell proliferation assay
MCF-7 cells were transduced with lentiCRISPRv2 containing
sgRNAs of interest (listed on Table 1). Separately, we generated MCF-
7 cells stably expressing GFP using pLX304-GFP (gift from David Root;
Addgene plasmid #25890). GFP-expressing cells were mixed with cells
containing individual lentiviral constructs in a 1:3 ratio. The percentage
of GFP-expressing cells was assessed by ﬂow cytometry at the beginning
of the experiment (T= 0) and at subsequent time-points. We recorded
at a minimum of 10,000 events for each condition, and the data were
analyzed using FlowJo software.
2.8. Luciferase reporter assays
A DNA fragment (∼2 kb) containing CUTE was ampliﬁed by PCR
from gDNA of MCF-7 cells and cloned into pGL3-promoter using KpnI/
NheI. The constructs were transfected into MCF-7 cells and treated with
10−8 M E2 or vehicle (DMSO) for 24 h. Reporter activity was measured
40 h after transfection using Dual-Luciferase system (Promega) ac-
cording to the manufacturer's instructions.
2.9. RNA-seq
RNA-seq samples were processed with TruSeq RNA library prep kit
v2 (Illumina) and sequenced in a HiSeq 2500 (Illumina). Sequenced
reads were aligned to the human genome (hg19) using TopHat2 [26]
and gene expression counts were calculated using HTseq34 based on
Ensembl's human gene annotations (v69) [27]. Gene expression levels
were normalized by quantiles.
2.10. ChIP-seq experiments and data analysis
ChIP-seq of ERα, FOXA1 and H3K27ac in WT and mutant MCF-
7 cells were performed as described before [28] using the following
antibodies: ERα (SC-543; Santa Cruz Biotechnology); FOXA1 (SC-6554;
Santa Cruz Biotechnology); H3K27ac (39133; Active Motif). Sequen-
cing reads were aligned to the human genome (hg19) using bwa v 0.7.5
with default parameters. Peaks in control MCF-7 cells were called with
MACS36 (default parameters) and DFilter37 (parameters: −bs=50
−ks= 30−reﬁne−nonzero) algorithms. In-house MCF-7 mixed input
was used for peak calling of MCF-7 cell line. Intersect of the two peak
calling algorithms was used for further analysis. ChIP-seq data sets of
ERα-Vehicle and ERα-E2 in MCF-7 cells was obtained from GEO. The
raw ﬁles were aligned to hg19 using Bowtie [29]. Unique reads were
converted into bigWig ﬁles using BEDTools [30] for visualization in the
UCSC Genome Browser.
2.11. ChIA-PET data
ChIA-PET data (publicly available on the Washington University
Epigenome browser) of ERα and RNAPII in MCF-7 cells was reanalyzed
to identify long-range chromatin interactions at the CUTE locus.
2.12. DNase-seq data
DNase-seq data sets from the ENCODE project were reanalyzed to
identify open chromatin regions at the CUTE locus. Available tracks
were uploaded to the UCSC genome browser for visualization.
2.13. GRO-seq experiments and data analysis
GRO-seq experiments were performed as described before [20]. We
also used publicly available GRO-seq data of MCF-7 cells treated with
E2 that was obtained from Ref. [12]. Data points were downloaded
from the UCSC genome browser using table browser. Transcription le-
vels were quantiﬁed by calculating of the sum of data points per gene
and normalizing to their length.
2.14. Gene expression analysis of TCGA samples
The Regulome Explorer tool (explorer.cancerregulome.org) was
used to interrogate the TCGA database to ﬁnd correlations of gene ex-
pression in breast cancer samples (ID: BRCA). The identiﬁcation of
genes signiﬁcantly (p < 0.05) correlating with ESR1 expression was
restricted to genes located within 1Mb of CUTE.
3. Results
We previously conducted a CRISPR-Cas9 genetic screen for mito-
genic estrogen-responsive elements (EREs), and identiﬁed sgRNA1830
as a guide RNA aﬀecting the proliferation of ERα-positive breast cancer
cells [20]. Therefore, enh1830 (the target of sgRNA1830) is a potential
transcriptional enhancer that is essential for the mitogenic function of
ERα. To study the function of enh1830 in detail, we ﬁrst analyzed the
landscape surrounding its genomic locus. enh1830 is located within the
ﬁrst intron of CUEDC1 gene and is predicted to be an enhancer in dif-
ferent human cell types due to high H3K27Ac and low H3K4me3 marks
indicative of enhancers [31] (Fig. 1A). In line with this, we detected
transcription of enhancer RNAs (eRNAs) from enh1830 by global run
on sequencing (GRO-seq) in MCF-7 cells (Fig. 1A). Importantly, ele-
vated levels of eRNA expression were measured upon activation of ERα
by estradiol (E2) in MCF-7 cells, whereas in MDA-MB-231 (ERα-nega-
tive) they were not detectable (Fig. 1A, red arrows). Finally, we ob-
served that the binding of ERα at enh1830 overlaps with that of p300, a
known coactivator protein associated with enhancers [32]. We there-
fore named the region enh1830 as CUTE (CUEDC1 Transcriptional
Enhancer) and conclude that it is a putative enhancer regulated by ERα
in breast cancer cells.
Next, we examined the function of CUTE in heterologous reporter
assays. Enhancers are known to activate gene expression regardless of
their orientation relative to the target gene [33]. To address this point,
we cloned a DNA fragment of∼2 kb containing CUTE in either forward
or reverse orientation upstream of a luciferase reporter gene of a pGL3-
promoter plasmid. We transfected these constructs into MCF-7 cells and
observed a strong activation of luciferase expression (∼8 fold; P-
value< 0.001) independently of the orientation of CUTE (Fig. 1B).
Next, we tested the responsiveness of CUTE to estrogen activation by
treating transfected MCF-7 cells with estradiol (E2). We observed a
strong increase (∼30 fold; P-value<0.001) in the expression of luci-
ferase pGL3 vectors containing CUTE (Fig. 1C), indicating that the
transcriptional enhancer activity of CUTE is dependent of ERα. To
conﬁrm this hypothesis, we generated mutations in the estrogen-re-
sponsive element (ERE) of CUTE by CRISPR-Cas9 and cloned the
Table 2
Primers used for qPCR experiments.
CUEDC1 Forward aaggaactgcaacggaacc
CUEDC1 Reverse ggattcgtatttcaatcgatctct
CUTE Forward acaccagcttcctggttcc
CUTE Reverse ctgaggtccttccctgcac
TBP Forward ggagagttctgggattgtac
TBP Reverse cttatcctcatgattaccgcag
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mutant sequences in pGL3. Luciferase reporter assays showed a drastic
reduction in their transcriptional activity (Fig. 1D), which conﬁrms that
CUTE is as a bona ﬁde enhancer regulated by ERα.
To further assess the eﬀect of sgRNA1830 on its target (the ERE of
CUTE), we transduced MCF-7 cells with sgRNA1830 and performed
next-generation DNA sequencing in this region (Fig. 2A, Supplementary
Fig. S1A). We observed that the vast majority of deletions generated by
Cas9 are small (≤15 bp) and map to the expected cleavage site
(Supplementary Fig. S1B). Next, we performed ChIP-seq for ERα in
MCF-7 cells transduced with sgRNACtrl and sgRNA1830 (MCF-7sgCtrl
and MCF-7sg1830, respectively) to assess the speciﬁcity of CRISPR-Cas9
targeting. Reassuringly we found that the binding of ERα is sig-
niﬁcantly decreased only at the CUTE locus in MCF-7sg1830 cells
(Pearson=0.91; P-value=0) (Fig. 2B, Supplementary Fig. S1D). More
importantly, two other hits from our previous screen [20] (enh588 and
enh1986) remained unchanged, conﬁrming speciﬁcity of the eﬀect on
the phenotype. It is known that the binding of ERα is frequently
associated with FOXA1, which is thought to be required for the acti-
vation of target genes of estrogen [34]. Intriguingly, FOXA1 binding to
CUTE was also speciﬁcally decreased in MCF7sg1830 cells
(Pearson=0.94; P-value=0) (Fig. 2C, and Supplementary Fig. S1E).
These results suggest that the disruption of ERα binding causes loss of
FOXA1, which can in turn aﬀect the transcriptional activity of CUTE.
Consistent with this hypothesis, we also found that the activating his-
tone mark H3K27Ac is signiﬁcantly decreased at the CUTE locus in
MCF-7sg1830 cells (Pearson=0.96; P-value= 0) (Fig. 2D). So far our
results indicate that sgRNA1830 speciﬁcally impairs the binding of ERα
to CUTE, which leads to reduced transcriptional activity and loss of
enhancer identity.
The identiﬁcation of functional enhancers and their target genes is a
major challenge in the ﬁeld of transcriptional research [35]. Therefore,
we combined multiple experimental techniques to identify the target
gene of CUTE in breast cancer cells. First, we reanalyzed chromatin
interactions identiﬁed by ChIA-PET and found that the CUTE locus
Fig. 1. CUTE is a putative enhancer element regulated by ERα. (A) RefSeq genes track from NCBI showing the genomic location of sgRNA1830 (red vertical line) and
CUTE (zoomed in window). Chromatin State Segmentation by a hidden Markov model from ENCODE/Broad in nine human cell-types. Color code: yellow/orange -
enhancer; green - active transcription; blue - insulator; grey - low signal. ChIP-seq of ERα and FOXA1 in MCF-7 cells treated with E2. The lower track corresponds to
ChIP-seq data of p300 in MCF-7 cells. GRO-seq of MCF-7 cells treated with E2 (in red) and normal medium (in blue). The bottom track corresponds to GRO-seq data in
MDA-MB-231 cells. (B) MCF-7 cells were co-transfected with Renilla and pGL3-based vectors and luciferase activities were measured after 48 h. The SV40 enhancer
(pGL3-SV40) was used as a positive control in this assay. The relative luciferase activities (Renilla/ﬁreﬂy) were normalized to pGL3-empty. Data represent
mean ± s.d of n= 3. ***P < 0.001, relative to pGL3-empty. Fw, forward. RV, reverse. (C) MCF-7 cells were co-transfected with Renilla and pGL3-based vectors and
treated with vehicle or E2 for 24 h. The relative luciferase activities (Renilla/ﬁreﬂy) were normalized to pGL3-empty vehicle. Data represent mean ± s.d of n = 3.
***P < 0.001, relative to pGL3-empty vehicle. (D) Schematic representation of pGL3-CUTE constructs used in the reporter assays. The mutant sequences of CUTE
(mut. #4 and #6) were generated by CRISPR-Cas9 gene editing in MCF-7 cells, ampliﬁed by PCR and cloned into pGL3-promoter. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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interacts with several regions nearby CUEDC1 (Fig. 3A). Interestingly,
the interactions with the promoter of CUEDC1 involve both ERα and
RNAPII, suggesting that they might be functionally relevant. Then, we
performed RNA-seq experiments in MCF-7sgCtrl and MCF-7sg1830 cells in
order to identify genes regulated by CUTE. We analyzed changes in
gene expression in the vicinity of CUTE (± 500 kb) and found that
CUEDC1 was the most downregulated gene in MCF-7sg1830 cells
(Fig. 3B). We conﬁrmed by qPCR analysis that the expression of
CUEDC1 is signiﬁcantly decreased in MCF-7sg1830 cells (∼70%; P-
value<0.01) (Fig. 3C). On the other hand, sgRNA1830 had no sig-
niﬁcant eﬀect on CUEDC1 expression in MDA-MB-231 cells, despite
having sgRNA1830-induced mutations (Fig. 3D, Supplementary Fig.
S1C), which suggests that CUTE is an active enhancer only in ERα-
positive cells. In line with this, we found a signiﬁcant decrease in CUTE
expression in MCF-7sg1830 (Fig. 3C) but not in MDA-MB-231sg1830 cells
(Fig. 3D). Next, we reanalyzed publicly available GRO-seq data of MCF-
7 cells treated with E2 in order to identify target genes of ERα. We
focused our attention on the CUTE locus (± 500 kb) and identiﬁed
CUEDC1 as the most upregulated gene upon ERα activation (Fig. 3E).
Then, we tested whether the expression of CUTE and CUEDC1 depend
on ERα function by removing E2 from the culture medium of MCF-7
and MDA-MB-231 cells. We found that both CUTE and CUEDC1 ex-
pression were signiﬁcantly downregulated in MCF-7 cells, but not in
MDA-MB-231 cells upon 72 h of E2 depletion (Fig. 3F–G). We validated
this result by performing a time-course experiment in MCF-7 and MDA-
MB-231 cells treated with E2 after estrogen depletion. Indeed, CUEDC1
expression was signiﬁcantly increased (∼2.5 fold) already 4 h after E2
treatment and remained high over the course of 24 h (Fig. 3H), in-
dicating that CUEDC1 is a primary target gene of ERα. The expression
of eRNAs transcribed from CUTE followed a similar pattern in MCF-
7 cells (Fig. 3H), supporting the notion that CUTE is responsive to ERα.
Importantly, neither CUTE nor CUEDC1 expression showed any sig-
niﬁcant alteration in MDA-MB-231 cells (Fig. 3I). These results suggest
that CUTE mediates the activation of CUEDC1 in response to ERα sti-
mulation. In order to test this hypothesis, we treated estrogen-depleted
MCF-7sgCtrl and MCF-7sg1830 cells with E2 (24 h) and measured the ex-
pression of CUTE and CUEDC1 by qPCR. Reassuringly, we found that
the induction of CUTE and CUEDC1 expression by E2 was severely
compromised in MCF-7sg1830 cells (Fig. 3J), whereas in MDA-MB-
231 cells no signiﬁcant change in their expression was observed
(Fig. 3K). Altogether, our experiments establish CUTE as an ERα-de-
pendent enhancer mediating CUEDC1 activation in breast cancer cells.
In a previous work, we showed that the disruption of CUTE by
CRISPR-Cas9 (sgRNA1830) is associated with decreased proliferation of
MCF-7 cells [20]. Given that CUTE is an enhancer of CUEDC1, we hy-
pothesized that this gene is required for ERα-mediated cell prolifera-
tion. Accordingly, we designed two sgRNAs targeting the coding se-
quence of CUEDC1 (sgRNACUEDC1 exon#1 and exon#2), and as a
control we used two sgRNAs targeting introns nearby CUTE (sgRNAC-
UEDC1 intron#1 and intron#2) (Fig. 4A). We observed a signiﬁcant
decrease in the proliferation of MCF-7 cells transduced with the sgRNAs
targeting the exons of CUEDC1, but not with those targeting the introns
(Fig. 4B). This eﬀect on proliferation is similar to the one caused by
inactivating CUTE (Fig. 4B), indicating that CUEDC1 is required for
optimal cell proliferation and is likely to be the mediator of CUTE-in-
duced cell proliferation phenotype. To assess the speciﬁcity of the im-
pact of CUEDC1-exon targeting, we measure RNA levels by qRT-PCR.
Out-of-frame mutations induced by CRISPR-Cas9 are expected to
trigger reduced levels of mRNA expression due to the nonsense medi-
ated mRNA decay pathway [36]. Indeed, CUEDC1 levels were markedly
reduced by sgRNAs targeting its exons (2.5–3 fold, Fig. 4C). This eﬀect
was speciﬁc since targeting the introns did not change signiﬁcantly the
expression of CUEDC1 (Fig. 4D). Moreover, no eﬀect was observed on
the expression of eRNAs (Fig. 4C–D), indicating that the transcriptional
activity of CUTE was not aﬀected. Next, we ectopically expressed
CUEDC1 in MCF-7sg1830 and observed a complete rescue of the pro-
liferative defect phenotype (Fig. 4E). To test speciﬁcity of the rescue
mediated by CUEDC1 ectopic expression, we mutated the CUE domain
(CUEDC1mut) which is the only functional domain currently known for
this protein (Fig. 4E). The ectopic expression of CUEDC1mut in MCF-
7sg1830 cells was not able to rescue the proliferation defect (Fig. 4E),
suggesting that the CUE domain is required for the proper function of
CUEDC1 in breast cancer cells. It was previously reported that CUEDC1
interacts with TOM1 - a protein suggested to be involved in cellular
traﬃcking [25]. In co-IP experiments, we observed that CUEDC1mut
binds to TOM1 in a similar extent as wild type CUEDC1 (Fig. 5A), which
indicates that the CUE domain is dispensable for the interaction with
TOM1. Altogether, our results demonstrate that activation of CUEDC1
expression is essential for ERα-mediated stimulation of cellular pro-
liferation.
Finally, we examined the expression levels of ERα and CUEDC1 in a
publicly available breast cancer cohort (TCGA, http://xenabrowser.net)
and we expected to have a positive correlation according to our ﬁndings
above. Indeed, CUEDC1 expression was positively associated with ERα
(R=0.29; P-value=10−199, Fig. 5B), suggesting that CUEDC1 is also a
target of the estrogen pathway in vivo.
4. Discussion
The identiﬁcation of direct target genes of the estrogen pathway is a
fundamental question in current breast cancer research [11]. Genome-
wide studies using GRO-seq identiﬁed∼3000 protein-coding genes that
are regulated by estrogen in breast cancer cells [11]. This number is
substantially higher than what was previously determined using ex-
pression microarrays and corresponds to∼33% of all expressed RefSeq
genes in MCF-7 [12]. Despite these advances, it is still not clear which
are the direct functional targets of this pathway as ERα binds mostly to
distal enhancer elements [8,9]. Recently, we showed that functional
enhancers can be annotated in an unbiased manner by CRISPR-Cas9
screens [20,37]. Moreover, we demonstrated that combining genome
editing technologies with gene expression analysis is a powerful method
to identify the target genes of enhancers. Here, we extended our
Fig. 2. The disruption of ERα binding at the CUTE locus is associated with loss of FOXA1 and H3K27Ac. (A) Schematic representation of the targeting of CUTE by
CRISPR-Cas9 (sgRNA1830). (B-D) ChIP-seq of ERα (C), FOXA1 (D) and H3K27Ac (E) in MCF-7CNT and MCF-7sg1830 cells. e588 - ERE 588. e1830 - ERE 1830. e1986 -
ERE 1986. CPM, counts per million. Pearson, Pearson number. P, P-value.
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strategy to characterize CUTE, an ERα-bound enhancer previously
identiﬁed in our screen [20]. Several lines of evidence suggest that
CUTE controls the expression of CUEDC1 in response to estrogen sig-
naling, and that this interaction is essential for ERα-mediated stimu-
lation of cell proliferation. First, ERα binds robustly to CUTE in MCF-
7 cells as detected by ChIP-seq experiments (Fig. 1A). Second, binding
of ERα to CUTE is signiﬁcantly decreased by mutations in the ERE
(Fig. 2B). Third, chromatin interactions between CUTE and the pro-
moter of CUEDC1 involve ERα (Fig. 3A). Fourth, activation of CUEDC1
expression by estrogen relies entirely on the ERE of CUTE (Fig. 3J).
Finally, the expression of CUEDC1 correlates positively with ERα
expression in breast tumors (Fig. 5B). Altogether, our results strongly
imply that CUEDC1 is a direct functional target of estrogen in breast
cancer cells (Fig. 5C).
Our results suggest that CRISPR-Cas9 has a high speciﬁcity of tar-
geting at enhancer elements. This is supported by ChIP-seq data
showing that ERα binding is speciﬁcally decreased at the CUTE region
by sgRNA1830. The fact that a single locus is aﬀected by CRISPR-Cas9
is quite remarkable since ERα binds to tens of thousands of EREs across
the genome [38]. We observed similar eﬀects at additional ERα-regu-
lated enhancers in multiple breast cancer cell lines [20], further sup-
porting the application of CRISPR-Cas9 to study transcriptional
Fig. 3. CUTE is an ERα-responsive enhancer that regulates the expression of CUEDC1 (A) ChIA-PET data of ERα and RNAPII in MCF-7 cells. Violet arcs represent
long-range chromatin interactions that are statistically signiﬁcant. (B) RNA-seq was performed in MCF-7CNT and MCF-7sg1830 cells. Diﬀerential expression analysis
was restricted to genes located−/+ 500 Kb of CUTE. ACTB was used as a negative control. (C) Expression analysis of CUTE eRNA and CUEDC1 mRNA in WT (CNT)
and mutant (sgRNA1830) MCF-7 cells. Data represent mean ± s.d of n= 3. **P < 0.01. ***P < 0.001. (D) Expression analysis of CUTE eRNA and CUEDC1mRNA
in WT (CNT) and mutant (sgRNA1830) MDA-MB-231 cells. Data represent mean ± s.d of n=3. n. s., not signiﬁcant. (E) Relative mRNA expression measured by
GRO-seq in MCF-7 cells treated with vehicle (Veh) and estradiol (E2). Diﬀerential gene expression analysis was restricted to genes located −/+ 500 Kb of CUTE.
ACTB was used as a negative control. (F) Expression analysis of CUTE eRNA and CUEDC1 mRNA in MCF-7 cells treated with complete (DMEM) and conditioned
medium (E2 depletion). Data represent mean ± s.d of n = 3. *P < 0.05, ***P < 0.001. (G) Expression analysis of CUTE eRNA and CUEDC1 mRNA in MDA-MB-
231 cells treated with complete (DMEM) and conditioned medium (E2 depletion). Data represent mean ± s.d of n=3. n. s., not signiﬁcant. (H) Analysis of CUTE
eRNA and CUEDC1 mRNA expression by qPCR in MCF-7 cells treated with vehicle (Veh) or estradiol (E2). Gene expression levels are normalized to TBP. Data
represent mean ± s.d of n = 3. *P < 0.05, **P < 0.01., n. s., not signiﬁcant. Two-tailed Student's t-test relative to Vehicle-4h (I) Analysis of CUTE eRNA and
CUEDC1 mRNA expression by qPCR in MDA-MB-231 cells treated with vehicle (Veh) or estradiol (E2). Gene expression levels are normalized to TBP. Data represent
mean ± s.d of n=3. n. s., not signiﬁcant. Two-tailed Student's t-test relative to Vehicle-4h. (J) Analysis of CUTE eRNA and CUEDC1 mRNA expression by qPCR in
MCF-7CNT and MCF-7sg1830 cells treated with vehicle (Veh) or estradiol (E2). Expression levels are normalized to TBP and compared to CNT-Veh. Data represent
mean ± s.d of n = 3. *P < 0.05. **P < 0.01. ***P < 0.001. n. s., not signiﬁcant. (K) Analysis of CUTE eRNA and CUEDC1 mRNA expression by qPCR in MDA-
MB-231CNT and MDA-MB-231sg1830 cells treated with vehicle (Veh) or estradiol (E2). Expression levels are normalized to TBP and compared to CNT-Veh. Data
represent mean ± s.d of n=3. n. s., not signiﬁcant. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of
this article.)
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enhancers [37]. The loss of ERα binding is associated with a con-
comitant decrease in the signal of FOXA1 and H3K27Ac at the CUTE
locus of targeted cells (MCF-7sg1830). FOXA1 is a pioneer factor that is
required for ERα-mediated gene regulation [34], whereas H3K27Ac is a
mark frequently associated with active enhancers [39,40].
Additionally, we found that the expression of eRNAs is decreased in
MCF-7sg1830 cells, suggesting that RNA polymerase II (RNAPII) activity
is impaired at the CUTE locus. We conclude that ERα is an essential
component of CUTE since the disruption of its binding leads to loss of
enhancer-associated marks and decreased transcriptional activity.
Fig. 4. CUEDC1 is required for the growth of MCF-7 cells. (A) Schematic representation of the CUEDC1 mRNA and the sgRNAs targeting it (B) MCF-7 cells were
transduced with the indicated sgRNAs and allowed to proliferate for nine days. Cell growth is represented as percentage of GFP, which is normalized to the beginning
of the experiment (T=0). (C) Expression analysis of CUTE eRNA and CUEDC1 mRNA by qPCR in MCF-7 cells transduced with sgRNAs targeting an exon of CUEDC1.
Data represent mean ± s.d of n = 3. ***P < 0.001. n. s., not signiﬁcant. (D) Expression analysis of CUTE eRNA and CUEDC1 mRNA by qPCR in MCF-7 cells
transduced with sgRNAs targeting an intron of CUEDC1. Data represent mean ± s.d of n=3. n. s., not signiﬁcant. (E) MCF-7 cells were sequentially transduced with
the indicated sgRNAs and with pLX304-GAPDH, pLX304-CUEDC1 or pLX304-CUEDC1mut. The cells were allowed to proliferate for nine days and their growth is
represented as percentage of GFP (normalized to T=0). Data represent mean ± s.d of n=3. Western blot analysis of MCF-7 cells expressing the diﬀerent constructs
is shown on the side. The V5 tag was used to detect expression of the proteins. (F) Schematic representation of the mutations generated in the CUE domain, which
convert a di-leucine to a di-alanine motif.
Fig. 5. CUEDC1 expression is signiﬁcantly increased in ERα-positive tumors (A) HEK-293 T cells were transfected with V5 tagged CUEDC1 and control GAPDH
vectors. Cells were extracted and subjected to co-immuno-precipitation and blotting analysis with anti-TOM1 and anti-V5 antibodies. (B) The expression of CUEDC1
and ESR1 was compared in 1219 samples from the TCGA (R=0.29; P-value= 10−199). (C) Graphic model depicting the role of CUTE (enh1830) and enh588 [20] in
controlling cell proliferation.
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However, it is possible that there are additional sequences, besides the
ERα binding site, which are critical for the activity of CUTE. This
question can be addressed by saturation mutagenesis experiments using
CRISPR-Cas9, which allow to identify critical regulatory elements at
near-nucleotide resolution [19,20,22].
The concept of “super-enhancers” has been recently proposed to
describe regulatory elements that drive exceptionally high levels of
transcription [41–43]. Super-enhancers typically comprise a cluster of
regulatory elements, spanning up to 12.5 kb, which exhibit highly sy-
nergistic activities [44]. Our results suggest that CUTE is a strong en-
hancer in human cells: in reporter assays, it is able to activate gene
expression in a robust manner (∼30 fold upon E2 stimulation); genetic
alterations in its sequence cause a dramatic reduction in CUEDC1 ex-
pression (∼70%). Interestingly, we noted that the CUTE locus fulﬁls
the bioinformatic criteria of super-enhancers: extended signal of
H3K27Ac (∼8 kb), multiple DNAse Hypersensitive sites (DHSs) located
in close proximity (∼4 kb) and binding of RNAPII [41]. Moreover, the
two DHSs in the vicinity of CUTE are also bound by cell-type-speciﬁc
TFs (e.g. FOXA1, GATA3) and co-activator p300. Given the available
evidence, it is tempting to speculate that these DHSs are enhancers that
collaborate with CUTE to regulate CUEDC1 expression in breast cancer
cells. However, further experiments (e.g. deletion of each constituent
element) are required to clarify whether they are functional elements
and whether they act as a super-enhancer of gene expression [45,46].
The disruption of CUTE by CRISPR-Cas9 is associated with de-
creased cell proliferation, and our results strongly suggest that this is
due to decreased expression of CUEDC1. To date, not much is known
about the molecular mechanisms that underpin the function of
CUEDC1, though available evidence points in the direction of the ubi-
quitin pathway. CUE domains are sequences of ∼40 amino acids that
bind monoubiquitin in yeast and human [47] and regulate chain for-
mation by E3 ligases [23]. Interestingly, CUEDC1 was recently identi-
ﬁed in a proteome-wide screen for ubiquitin interactors [24]. Zhang
and colleagues showed that CUEDC1 binds to K33 and K63 diubiquitin
in diﬀerent human cell-types, suggesting that it might be involved in
protein traﬃcking, signal transduction and degradation pathways [48].
This hypothesis is also supported by our results showing an interaction
between CUEDC1 and TOM1. The connection of CUEDC1 with cancer is
thin; however, its expression is positively correlated with ERα in breast
tumors (Fig. 5B) and is signiﬁcantly upregulated in metastatic cervical
tumors compared to primary tumors [49]. These results support our
ﬁndings and suggest that CUEDC1 is a downstream target of ERα mi-
togenic function, although additional studies are required to clarify its
role in cell proliferation and tumor development (Fig. 5C).
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